Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany.
- DOI
- 10.1080/20523211.2026.2651404
- Published
- 2026
- Container
- Journal of pharmaceutical policy and practice
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/20523211.2026.2651404,
title = {Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany.},
author = {Ardito V and Falk L and Gasol Boncompte M and Pontes C and Robinson J and Schreyögg J and Ciani O},
year = {2026},
journal = {Journal of pharmaceutical policy and practice},
doi = {10.1080/20523211.2026.2651404},
url = {https://doi.org/10.1080/20523211.2026.2651404}
}RIS
TY - JOUR TI - Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany. AU - Ardito V AU - Falk L AU - Gasol Boncompte M AU - Pontes C AU - Robinson J AU - Schreyögg J AU - Ciani O PY - 2026 JO - Journal of pharmaceutical policy and practice DO - 10.1080/20523211.2026.2651404 UR - https://doi.org/10.1080/20523211.2026.2651404 ER -
APA
V, A., L, F., M, G. B., C, P., J, R., J, S., & O, C. (2026). Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany.. Journal of pharmaceutical policy and practice. https://doi.org/10.1080/20523211.2026.2651404
Source records
- pubmed · retrieved 2026-09-26T16:26:35.945Z